GNAI1

GNAI1 encodes Gαi1, a heterotrimeric G protein α-subunit whose core activity is GTP binding and hydrolysis, a nucleotide cycle required for productive interaction with partners that recognize the GDP- or GTP-loaded states and for plasma membrane localization (PMID:34685729). Gαi1 transduces inhibitory dopamine D2 receptor signaling, and disease-associated missense variants alter this transduction in opposite directions—producing gain-of-function increases in agonist potency and constitutive activity (T48K, T48I, C224Y, V332E) or loss of receptor responsiveness (G40C)—while nearly all variants impair GTP binding and hydrolysis (PMID:41329793). Independently, GNAI1 is required for ciliogenesis: patient variants disrupt cilia assembly and function in C. elegans neurons and abolish ciliary localization of Gαi1 in human cells, defining cilia dysfunction as a distinct pathogenic axis (PMID:41052774, PMID:40894620). Beyond canonical signaling, GNAI1 (with GNAI3) restrains the IL6/JAK2–STAT3 and NF-κB axes; combined loss activates these pathways through downstream GNAI2 (PMID:30836096), and GNAI1 acts as a suppressor of adenylate cyclase whose inhibition de-represses cAMP/PKA/CREB signaling (PMID:35678269). GNAI1 physically associates with β-arrestin-1 (ARRB1) in a complex coupled to pro-survival ERK/JAK2-STAT3/mTOR signaling (PMID:42088441).

1. 2012 Medium

   Established GNAI1 as a functional suppressor of tumor cell motility and identified a post-transcriptional control mechanism, framing it as more than a passive signaling node.

   Evidence Gain- and loss-of-function with Transwell migration/invasion assays plus miR-320 mimic experiments in hepatocellular carcinoma cells

   PMID:23691483

   Open questions at the time

   • Molecular mechanism linking GNAI1 to migration not defined
   • miR-320 targeting shown at protein level without 3'UTR reporter
   • Single cancer context
2. 2019 High

   Placed GNAI1 (with GNAI3) as an upstream brake on inflammatory signaling, answering whether these subunits regulate JAK2/STAT3 and NF-κB and establishing a GNAI2-dependent downstream relay.

   Evidence Reciprocal Co-IP with IL6 pathway proteins plus genetic epistasis using double and conditional knockout mice with immunoblot, flow cytometry, and ELISA

   PMID:30836096

   Open questions at the time

   • Direct GNAI1 substrate within the axis not defined
   • Functional redundancy with GNAI3 not fully resolved
   • Mechanism of pathway repression at molecular level unclear
3. 2021 Medium

   Defined the biochemical consequence of pathogenic mutations by showing Gln52 substitutions abolish GTP binding/hydrolysis, mislocalize the protein, and break partner interactions—anchoring nucleotide cycling as the core function.

   Evidence GTP binding/hydrolysis assays, Co-IP with partners, and subcellular localization of mutant vs. wild-type Gαi1 in cell lines

   PMID:34685729

   Open questions at the time

   • Single lab
   • Partner identities transducing the defect not fully enumerated
   • In vivo phenotype of mutants not tested
4. 2022 Medium

   Demonstrated that GNAI1's inhibition of adenylate cyclase can be pharmacologically relieved, validating the cAMP/PKA/CREB axis as a druggable output of Gαi1 activity.

   Evidence DARTS-MS target identification, cAMP measurement, CREB phosphorylation, and PKA-inhibitor rescue in podocytes and diabetic mouse kidney

   PMID:35678269

   Open questions at the time

   • Single lab
   • Binding site on GNAI1 not mapped
   • Selectivity of the small molecule for GNAI1 vs. other Gα not established
5. 2025 High

   Resolved how syndrome variants alter receptor-coupled signaling by reconstituting D2R–Gαi1 coupling, revealing both gain- and loss-of-function variant classes and distinguishing them from their nucleotide-handling defects.

   Evidence Xenopus oocyte electrophysiology of D2R plus variant Gαi1, GTP-γ-S binding assays, and in silico modeling

   PMID:41329793

   Open questions at the time

   • Mechanism of constitutive activity for individual variants not structurally defined
   • Receptor coupling tested only for D2R
   • Cellular consequences in patient-relevant cell types not assessed
6. 2025 High

   Identified ciliogenesis as a distinct GNAI1 requirement, separating variants that disrupt cilia assembly/localization from those that do not and adding cilia dysfunction as a pathogenic axis independent of signaling potency.

   Evidence CRISPR-Cas9 knock-in of patient variants in C. elegans AWC neurons with morphology and chemotaxis assays, plus ciliary localization imaging in human ciliated cell lines

   PMID:40894620 PMID:41052774

   Open questions at the time

   • Molecular mechanism of Gαi1 in cilia assembly not defined
   • Relationship between ciliary and D2R-signaling defects unresolved
   • Ciliary partners of Gαi1 not identified
7. 2026 Medium

   Revealed a GNAI1-ARRB1 complex coupled to pro-survival signaling, showing that disrupting this physical interaction shifts cells toward autophagic death.

   Evidence DARTS, CETSA, and docking for direct binding plus Co-IP for GNAI1-ARRB1 complex disruption in NSCLC models

   PMID:42088441

   Open questions at the time

   • Single lab
   • Direct vs. indirect nature of GNAI1-ARRB1 contact not structurally mapped
   • Mechanism connecting complex dissociation to autophagy not fully defined

• How GNAI1's distinct roles—nucleotide cycling at GPCRs, adenylate cyclase inhibition, ciliary function, and ARRB1/inflammatory pathway regulation—are integrated, and which are primary drivers of the GNAI1 syndrome phenotype, remains unresolved.
• No structural model linking variant class to specific phenotype
• Tissue-specific contributions of each axis unknown
• Direct molecular role of Gαi1 in cilia uncharacterized